Product image of Icatibanto Hikma (Icatibant) supplied by GNH India

Icatibanto Hikma

Active Ingredient:
Icatibant
Origin:
EU

Icatibanto Hikma (Icatibant)

Icatibant, the active ingredient in Icatibanto Hikma, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema attacks in patients with C1‑inhibitor deficiency, reducing swelling and improving airway safety.

GNH India supplies Icatibanto Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides regulated sourcing, quality assurance and global logistics to meet clinical demand.

Manufacturer / TM Owner

Hikma Farmacêutica (Portugal), S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to manage hereditary angioedema by blocking the bradykinin pathway that causes swelling.

  • Acute hereditary angioedema attacks (type I): rapid reduction of edema and pain.
  • Acute hereditary angioedema attacks (type II): relief of airway obstruction risk.
  • Hereditary angioedema with C1‑inhibitor deficiency: restores vascular stability during episodes.

How It Works

  • Icatibant selectively antagonizes the bradykinin B2 receptor, preventing bradykinin from binding and triggering its downstream signaling. By blocking this receptor, the drug inhibits the bradykinin‑mediated increase in vascular permeability and edema formation, thereby mitigating the swelling characteristic of hereditary angioedema attacks.

Side Effects

Common side effects are generally mild and related to the injection site or systemic response.

Common Side Effects

  • Injection site pain: discomfort at the site of subcutaneous administration.
  • Redness or erythema: localized skin irritation.
  • Swelling at injection site: transient edema.
  • Nausea: mild gastrointestinal upset.
  • Headache: transient cephalic discomfort.
  • Dizziness: brief sensation of light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reaction: rash, itching, or hives.
  • Anaphylaxis: severe, potentially life‑threatening allergic response.
  • Paradoxical angioedema: worsening swelling despite therapy.
  • Severe hypotension: marked drop in blood pressure.
  • Thrombocytopenia: reduced platelet count.
  • Acute respiratory distress: difficulty breathing unrelated to HAE.

Precautions & Warnings

Before using Icatibanto Hikma, consider the following safety measures.

  • Pregnancy: safety not established; avoid unless benefit outweighs risk.
  • Breastfeeding: unknown; evaluate potential infant exposure.
  • Renal impairment: use with caution and monitor renal function.
  • Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced edema.
  • Known hypersensitivity: discontinue immediately if severe allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibanto Hikma may interact with other medications that influence bradykinin pathways or fluid balance.

Major Interactions (Avoid)

  • ACE inhibitors: increased bradykinin may exacerbate edema.
  • Angiotensin receptor blockers: similar risk of heightened bradykinin effects.
  • Other bradykinin B2 antagonists: additive pharmacologic activity.

Moderate Interactions (Monitor Closely)

  • Diuretics: may alter fluid status and affect edema control.
  • Antihistamines: could mask mild hypersensitivity signs.
  • NSAIDs: monitor for potential renal effects when combined with bradykinin blockade.

Frequently Asked Questions

Icatibanto Hikma is indicated for the treatment of acute attacks of hereditary angioedema in patients who have a deficiency of C1‑inhibitor. It works by rapidly reducing swelling and preventing airway obstruction during an HAE episode.

Icatibant is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it stops bradykinin‑mediated increases in vascular permeability, which are responsible for the swelling seen in hereditary angioedema attacks.

The prescribed dose of Icatibanto Hikma is determined by the treating physician based on the patient’s clinical condition and regulatory guidelines. Dosing regimens are not disclosed here and should follow the prescriber’s instructions.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other therapies such as C1‑esterase inhibitor concentrates replace the deficient protein. Icatibant offers rapid subcutaneous administration and direct blockade of bradykinin, providing an alternative mechanism of action for patients who may not respond to protein‑based therapies.

Icatibanto Hikma should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Keep the product in its original packaging until ready for use to maintain stability.

The medication is supplied as a solution for subcutaneous injection. A healthcare professional administers the dose by injecting the prescribed volume into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique.

Serious risks include hypersensitivity reactions such as anaphylaxis, paradoxical worsening of angioedema, severe hypotension, and rare cases of thrombocytopenia. Patients should be monitored closely for any signs of these reactions, especially after the first dose.

Icatibanto Hikma is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Patients with a history of severe allergic reactions to bradykinin B2 antagonists should avoid its use, and the decision should be guided by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT